|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Carey LA et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329-34. Abstract
Esteva FJ et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005;7(4):R436-43. Abstract
Fehm T et al. Changes of serum HER2 status during clinical course of metastatic breast cancer patients. Anticancer Res 2004;24(6):4205-10. Abstract
Fornier MN et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005;16(2):234-9. Abstract
Gradishar W et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 12.
Kong SY et al. Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol 2006;59(4):373-6. Abstract
Lipton A et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005;104(2):257-63. Abstract
Mayer EL et al. Clinical trial update: Implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res 2007;9(5):110. Abstract
Meng S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004;101(25):9393-8. Abstract
Miller K et al. Capecitabine plus bevacizumab in first line metastatic breast cancer: An interim safety and efficacy report of the first phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. San Antonio Breast Cancer Symposium 2006;Abstract 2068.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Park H et al. Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: Biological and biochemical mechanisms of action. Cancer Res 2007;67(12):5717-26. Abstract
Sledge G et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. Proc ASCO 2007;Abstract 1013.
 |
 |
EDITOR'S NOTE
Peto’s curse
Neil Love, MD
- Select publications
INTERVIEWS
George W Sledge Jr, MD
- Select publications
William J Gradishar, MD
- Select publications
Lee S Schwartzberg, MD
- Select publications
FACULTY TUMOR PANEL
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
